Andrew Oxtoby

Board Member, Damien Center

Andrew Oxtoby has over two decades of experience in the health care and consumer products industries, including extensive global pharmaceutical experience with successful product launches, commercialization, and strategic planning. Mr. Oxtoby joined Aimmune in January 2019 as Chief Commercial Officer and built the commercial organization to prepare for the FDA approval and launch of PALFORZIA in January 2020, transforming Aimmune from a clinical-stage organization to a fully integrated commercial-stage biotechnology company.

In October 2020, Mr. Oxtoby was appointed President and Chief Executive Officer. Before joining Aimmune, Mr. Oxtoby spent 16 years at Eli Lilly and Company where, after having served as Vice President of US Diabetes Sales, he was responsible for Lilly’s US insulin business as Vice President of US Diabetes Connected Care and Insulins, an innovative, patient-focused business unit. While at Lilly, he also spent five years in oncology, including as Vice President of the International Oncology business, was General Manager of Lilly’s Netherlands operation, and held positions of increasing responsibility in marketing and sales.